|
|
||||||||
1 Laboratory of Physiology, Free University of Brussels, 2 Unit of Diabetes and Nutrition, Catholic University of Louvain, 3 Dept of Intensive Care of the Erasme University Hospital, Brussels, Belgium. 4 Unité de Réanimation de Chirurgie Cardiaque, Timone Hospital, Marseille, France
CORRESPONDENCE: R. Naeije, Laboratory of Physiology, Free University Brussels, Erasmus Campus CP 604, Lennik road 808, B-1070, Brussels, Belgium. Fax: 32 25554124. E-mail: rnaeije@ulb.ac.be
Keywords: endothelin, experimental, pulmonary arterial hypertension, pulmonary vascular impedance, serotonin, systemic-to-pulmonary shunting
Received: April 2, 2003
Accepted May 22, 2003
Abstract
The pathogenesis of pulmonary arterial hypertension (PAH) remains uncertain. Both the serotonin and endothelin (ET) systems are believed to be involved. Recent studies pointed to the importance of the serotonin 2B receptor as a limiting step.
The current authors investigated the lung tissue expression of serotonin receptors and of the serotonin transporter (5-HTT) by real-time-quantitative polymerase chain reaction in chronic overcirculation-induced PAH in growing piglets, with and without treatment with the dual ET receptor blocker bosentan. Pulmonary haemodynamic changes were described by pulmonary arterial impedance spectra.
Three months after the surgical anastomosis of the left subclavian artery to the pulmonary arterial trunk, there was a shift of the impedance spectra to higher ratios of pressure and flow moduli, with increases in both 0 Hz impedance and characteristic impedance, and these changes were completely prevented by bosentan therapy. There was an increase in the expression of the serotonin 1B receptor. There was no change in the expression of the 5-HTT, and of the serotonin 2B, 1D, and 4 receptors. The overexpression of the serotonin 1B receptor was partially prevented by bosentan therapy.
The present authors conclude that this early pulmonary arterial hypertension model is characterised by an endothelin receptor-dependent increased expression of the serotonin 1B receptor.
This article has been cited by other articles:
![]() |
A. Lawrie, E. Spiekerkoetter, E. C. Martinez, N. Ambartsumian, W. J. Sheward, M. R. MacLean, A. J. Harmar, A.-M. Schmidt, E. Lukanidin, and M. Rabinovitch Interdependent Serotonin Transporter and Receptor Pathways Regulate S100A4/Mts1, a Gene Associated With Pulmonary Vascular Disease Circ. Res., August 5, 2005; 97(3): 227 - 235. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. K. Weir, Z. Hong, and A. Varghese The Serotonin Transporter: A Vehicle to Elucidate Pulmonary Hypertension? Circ. Res., May 14, 2004; 94(9): 1152 - 1154. [Full Text] [PDF] |
||||
![]() |
G. Di Sacco Amfepramone does not cause primary pulmonary hypertension Eur. Respir. J., May 1, 2004; 23(5): 790 - 790. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |